JPMorgan raised the firm’s price target on Apellis (APLS) to $37 from $35 and keeps an Overweight rating on the shares. The firm updated the company’s model to reflect a December 2026 target versus 2025 previously.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Apellis price target raised to $40 from $39 at Cantor Fitzgerald
- Apellis price target lowered to $50 from $52 at Raymond James
- Steady Growth and Future Potential: A Hold Rating for Apellis Pharmaceuticals
- Cautious Outlook on Apellis Pharmaceuticals: Hold Rating Amidst Modest Syfovre Growth and Empaveli Expansion
- Apellis price target raised to $52 from $46 at Citi